NCT05567185 2026-03-13
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT05052372 2022-12-22
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
xCures
Terminated